- 标题
- 摘要
- 关键词
- 实验方案
- 产品
-
Photodynamic Therapy in the Treatment of Bladder Cancer: Past Challenges and Current Innovations
摘要： There are limited treatment options for patients with recurrent non-muscle-invasive bladder cancer. In this report, we will talk about the history of photodynamic therapy; although it showed encouraging therapeutic results, it was largely abandoned due to toxicity or bystander effects on normal cells. Monoclonal antibody-conjugates represent an emerging therapeutic approach for malignancies that improves upon tumor specificity. The use of a monoclonal antibody-photosensitizer conjugate is a more selective method of delivering light therapy and has been termed 'photoimmunotherapy', which we will discuss in the last part of this report.
关键词： Hematoporphyrin,Urothelial cancer,Hexaminolevulinic acid,Photoimmunotherapy,PIT,BCG-refractory NMIBC,PDT,Bladder cancer,5-Aminolevulinic acid,Photodynamic therapy
更新于2025-09-23 15:23:52
-
The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer – A New Analysis
摘要： Background: The International Bladder Cancer Group (IBCG) recently proposed a new de?nition of disease progression in non-muscle invasive bladder cancer (NMIBC), including change in T-stage, change to T2 or higher or change from low to high grade. Objective: To establish whether blue light cystoscopy with hexaminolevulinate (HAL) impacts the rate of progression and time to progression using the revised de?nition. Methods: An earlier long-term follow-up of a controlled Phase III study reported outcomes following blue light cystoscopy with HAL (255 patients) or white light (WL) cystoscopy (261 patients) in NMIBC patients. The data was re-analysed according to the new de?nition. Results: In the original analysis, after 4.5 years (median), eight HAL and 16 WL patients were deemed to have progressed (transition from NMIBC to muscle invasive bladder cancer, (T2-4)). According to the new de?nition, additional patients in both groups were found to have progressed: 31 (12.2%) HAL vs 46 (17.6%) WL (p = 0.085) with four (1.6%) HAL and 11 (4.2%) WL patients progressing from Ta to CIS. Time to progression was longer in the HAL group (p = 0.05). Conclusions: Applying the new IBCG de?nition there was a trend towards a lower rate of progression in HAL patients, particularly in those progressing from Ta to CIS. Time to progression was signi?cantly prolonged. This suggests that patients should receive blue light cystoscopy with HAL rather than WL at resection. Adoption of the new de?nition could allow more patients at risk of progression to be treated appropriately earlier.
关键词： NMIBC,blue light cystoscopy,Hexaminolevulinate,progression,bladder cancer
更新于2025-09-04 15:30:14